You're focusing on aducanumab but since them other similar drugs have been approved with similar results. I any case the debate is not on whether the drugs hav

You're focusing on aducanumab but since them other similar drugs have been approved with similar results. I any case the debate is not on whether the drugs have an impact on the disease (which they do, unequivocally), but on whether the risk/benefit ratio is good enough (on which I'm also not sold, but that's not the question in our discussion).